Literature DB >> 28696149

Immune checkpoint inhibitors: the battle of giants.

Matthieu Collin1.   

Abstract

Keywords:  PD-1; cancer; infringement; license; litigation; monoclonal antibodies; nivolumab; pembrolizumab

Mesh：

Substances：

Year:  2017        PMID： 28696149     DOI： 10.4155/ppa-2017-0015

Source DB:  PubMed          Journal:  Pharm Pat Anal        ISSN： 2046-8954


× No keyword cloud information.
  3 in total

1.  Cancer Stem Cells in the Immune Microenvironment.

Authors:  Dong-Sup Lee; Keunhee Oh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?

Authors:  Antonia Busse; Diana Lüftner
Journal:  Breast Care (Basel)       Date:  2019-02-13       Impact factor: 2.860

3.  A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab.

Authors:  Radomir Nykl; Ondrej Fischer; Karel Vykoupil; Milos Taborsky
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.